Phenylpiracetam (Phenotropil)

Phenylpiracetam (Carphedon, Phenotropil; (R/S)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide; CAS 77472-70-9; molecular formula C12H14N2O2; molecular weight 218.25) is a phenyl-substituted piracetam analog developed in the Soviet Union in the 1980s at the Russian Academy of Medical Sciences and registered in Russia and several former Soviet states under names including Phenotropil and Carphedon for asthenia, post-stroke cognitive impairment, attention deficit, and depression. The structural modification is the addition of a phenyl group at the 4-position of the pyrrolidinone ring, which produces a chiral center and substantially alters pharmacology relative to piracetam. The (R)-enantiomer carries the majority of the stimulant-like activity. Mechanism includes enhancement of dopamine, norepinephrine, and serotonin release in cortical regions through indirect mechanisms, AMPA receptor potentiation, and modest effects on GABA-A receptor subunits. The result is a clinical profile distinct from piracetam, with prominent stimulant character (improved physical endurance, attention, and mood elevation) in addition to the basic nootropic effects. Phenylpiracetam was banned by the World Anti-Doping Agency (WADA) in 2009 and remains on the prohibited list due to demonstrated performance enhancement in elite athletes. Pharmacokinetics: plasma half-life 3 to 5 hours; rapid oral absorption; both renal and hepatic excretion with no major active metabolites. The research literature reports dose ranges of approximately 100 to 300 mg. The clinical evidence base in Russian-language literature is substantial; English-language randomized trials are sparse.